Overview

Trial of Alvimopan in Major Spine Surgery

Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The Investigator has chosen to study the reconstructive spinal surgery patient population because it is believed that the use of alvimopan in these patients at the University of Virginia will give the scientific community significant insight into the broader applicability of this drug into other surgical populations, the impact of this drug on the perception of pain (as opposed to simply the consumption of opioids), and its impact on total hospital charges, resource utilization, and functional outcomes.
Phase:
Phase 4
Details
Lead Sponsor:
University of Virginia
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Alvimopan